Sequel Med Tech and Senseonics have partnered to develop the first automated insulin delivery system integrated with a one-year continuous glucose monitor, revolutionizing diabetes management options.
Innovative Integration Enhances Flexibility
The collaboration merges Sequel’s twiist Automated Insulin Delivery (AID) System with Senseonics’ Eversense 365 CGM, offering individuals with type 1 diabetes enhanced flexibility and personalization in managing their condition. This integration allows for seamless monitoring and insulin delivery, adapting in real-time to the user’s glucose levels.
Market Impact and Availability
Set to launch in the third quarter, the twiist™ system combined with Eversense 365 distinguishes itself as the first AID system compatible with a one-year CGM. Patients will have the option to choose between Senseonics’ Eversense 365 and Abbott’s FreeStyle Libre 3 Plus sensor, catering to diverse management needs.
Inferences:
- Compatibility with Eversense 365 may lead to increased user adherence due to reduced sensor replacement frequency.
- Real-time data integration can result in more precise insulin dosing, potentially lowering the risk of hyperglycemia and hypoglycemia.
- The partnership may encourage further innovations and collaborations within the diabetes technology sector.
This initiative underscores both companies’ dedication to advancing diabetes care by providing longer-lasting and more adaptable monitoring solutions. The integrated system aims to simplify the daily management of diabetes, offering users a more consistent and less invasive experience.
By combining Sequel’s state-of-the-art AID technology with Senseonics’ durable CGM, the partnership promises to enhance the quality of life for those managing type 1 diabetes. Patients can benefit from reduced maintenance and increased accuracy in glucose monitoring, leading to better overall health outcomes.
This development marks a significant milestone in diabetes treatment, offering a comprehensive solution that addresses both monitoring and insulin delivery needs. Users will gain greater autonomy and confidence in managing their condition, supported by cutting-edge technology designed for long-term use.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
